These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 8737200)

  • 21. Platelet glycoprotein IIb/IIIa receptor blockade and coronary resistance in unstable angina.
    Marzilli M; Sambuceti G; Testa R; Fedele S
    J Am Coll Cardiol; 2002 Dec; 40(12):2102-9. PubMed ID: 12505220
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The clinical role of platelet glycoprotein IIb/IIIa receptor inhibitors in ischemic heart disease.
    Lefkovits J; Topol EJ
    Cleve Clin J Med; 1996; 63(3):181-9. PubMed ID: 8665658
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The platelet, the patient, and periprocedural infarction during percutaneous transluminal coronary angioplasty.
    Fischman DL; Savage MP
    JAMA; 1997 Aug; 278(6):518-9. PubMed ID: 9256229
    [No Abstract]   [Full Text] [Related]  

  • 24. A comparison of abciximab and small-molecule glycoprotein IIb/IIIa inhibitors in patients undergoing primary percutaneous coronary intervention: a meta-analysis of contemporary randomized controlled trials.
    Gurm HS; Tamhane U; Meier P; Grossman PM; Chetcuti S; Bates ER
    Circ Cardiovasc Interv; 2009 Jun; 2(3):230-6. PubMed ID: 20031720
    [TBL] [Abstract][Full Text] [Related]  

  • 25. "IIb or not IIb or maybe IIb?" Is that the question? Or is it "which IIb and to whom?".
    Brinker JA
    Catheter Cardiovasc Interv; 2000 Oct; 51(2):145-6. PubMed ID: 11025565
    [No Abstract]   [Full Text] [Related]  

  • 26. Safety and efficacy of the platelet glycoprotein IIb/IIIa inhibitor abciximab in Chinese patients undergoing high-risk angioplasty.
    Chen YH; Chen JW; Wu TC; Ding PY; Wang SP; Chang MS
    Zhonghua Yi Xue Za Zhi (Taipei); 2000 Jan; 63(1):8-15. PubMed ID: 10645045
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Should glycoprotein IIb/IIIa inhibitors be used during all percutaneous coronary interventions? No.
    Ragosta M; Sarembock IJ
    J Thromb Haemost; 2004 Jan; 2(1):10-2. PubMed ID: 14717959
    [No Abstract]   [Full Text] [Related]  

  • 28. Should glycoprotein IIb/IIIa inhibitors be used during all percutaneous coronary interventions? Yes.
    Exaire JE; Lincoff AM
    J Thromb Haemost; 2004 Jan; 2(1):7-9. PubMed ID: 14717958
    [No Abstract]   [Full Text] [Related]  

  • 29. Use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
    Parmar R; Stouffer GA
    Am J Med Sci; 1997 Jul; 314(1):31-6. PubMed ID: 9216438
    [No Abstract]   [Full Text] [Related]  

  • 30. Abciximab therapy and unplanned coronary stent deployment: favorable effects on stent use, clinical outcomes, and bleeding complications. EPILOG Trial Investigators.
    Kereiakes DJ; Lincoff AM; Miller DP; Tcheng JE; Cabot CF; Anderson KM; Weisman HF; Califf RM; Topol EJ
    Circulation; 1998 Mar; 97(9):857-64. PubMed ID: 9521334
    [TBL] [Abstract][Full Text] [Related]  

  • 31. IIb/IIIa platelet inhibitors in the management of coronary artery disease.
    Talley JD
    J Ark Med Soc; 1996 Oct; 93(5):237-9. PubMed ID: 8908943
    [No Abstract]   [Full Text] [Related]  

  • 32. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization.
    EPILOG Investigators
    N Engl J Med; 1997 Jun; 336(24):1689-96. PubMed ID: 9182212
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Platelet glycoprotein IIb/IIIa receptor inhibitors in ischemic heart disease.
    Lefkovits J; Topol EJ
    Curr Opin Cardiol; 1995 Jul; 10(4):420-6. PubMed ID: 7549085
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Potent complementary clinical benefit of abciximab and stenting during percutaneous coronary revascularization in patients with diabetes mellitus: results of the EPISTENT trial.
    Lincoff AM
    Am Heart J; 2000 Feb; 139(2 Pt 2):S46-52. PubMed ID: 10650316
    [No Abstract]   [Full Text] [Related]  

  • 35. [Should treatment with glycoprotein IIa/IIIb receptor blocker be controlled in patients undergoing coronary intervention?].
    Heras M
    Rev Esp Cardiol; 2001 Nov; 54(11):1251-3. PubMed ID: 11707232
    [No Abstract]   [Full Text] [Related]  

  • 36. Clopidogrel treatment prior to percutaneous coronary intervention: when enough isn't enough.
    Steinhubl SR; Charnigo R
    JAMA; 2006 Apr; 295(13):1581-2. PubMed ID: 16533936
    [No Abstract]   [Full Text] [Related]  

  • 37. Risk of stroke associated with abciximab among patients undergoing percutaneous coronary intervention.
    Akkerhuis KM; Deckers JW; Lincoff AM; Tcheng JE; Boersma E; Anderson K; Balog C; Califf RM; Topol EJ; Simoons ML
    JAMA; 2001 Jul; 286(1):78-82. PubMed ID: 11434830
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Optimizing antiplatelet therapy in coronary interventions.
    King SB
    Clin Cardiol; 2000 Nov; 23 Suppl 6(Suppl 6):VI-8-13. PubMed ID: 11129685
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Frequency and efficacy of glycoprotein IIb/IIIa therapy for treatment of threatened or acute vessel closure in 1332 patients undergoing percutaneous transluminal coronary angioplasty.
    Haase KK; Mahrholdt H; Schröder S; Baumbach A; Oberhoff M; Herdeg C; Karsch KR
    Am Heart J; 1999 Feb; 137(2):234-40. PubMed ID: 9924156
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Care of the patient receiving ReoPro following angioplasty.
    Brezina K; Murphy M; Stonner T
    J Invasive Cardiol; 1994; 6 Suppl A():38A-42A; discussion 54A-56A. PubMed ID: 10155094
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.